The assessment of state and factors influencing on health-related quality of life in outpatients with hepatocellular carcinoma at 108 Military Central Hospital, 2022

  • Nguyễn Thị Loan Bệnh viện Trung ương Quân đội 108
  • Chu Việt Anh Bệnh viện Trung ương Quân đội 108
  • Nguyễn Ngọc Mai Bệnh viện Trung ương Quân đội 108
  • Vũ Thị Hồng Bệnh viện Trung ương Quân đội 108
  • Trần Thị Việt Trinh Bệnh viện Trung ương Quân đội 108
  • Phạm Thị Thùy Dương Bệnh viện Trung ương Quân đội 108
  • Nguyễn Thị Hường Bệnh viện Trung ương Quân đội 108
  • Nguyễn Thị Thùy Bệnh viện Trung ương Quân đội 108
  • Nguyễn Thúy Lệ Bệnh viện Trung ương Quân đội 108
  • Lê Duy Cương Bệnh viện Trung ương Quân đội 108

Main Article Content

Keywords

Hepatocellular carcinoma, health-related quality of life, outpatients, 108 Military Central Hospital

Abstract

Objective: To evaluate status and factors influencing on health-related quality of life (HRQoL) in outpatients with hepatocellular carcinoma (HCC) at 108 Military Central Hospital, 2022. Subject and method: A cross-sectional descriptive-analytic case-control study of 166 outpatients with HCC and 51 healthy > 18 years old. Assessing HRQoL by using the EQ-5D-5L and VAS health scale for Vietnamese people. Result: Mean age (61.43 ± 11.50), male rate (92.77%), Child-Pugh A (91.5%) and stage 3 of BCLC (59.64%). The patient's EQ-5D-5L and VAS scores were reduced more significantly than those of control group (p=0.000). Factors were to reduce HRQoL included: Older age (p=0.000), singleness (p=0.000), low education status (p=0.026 and p=0.046), poor income (p=0.008 and 0.018), longer duration of disease (p=0.027 and 0.03), longer duration of disease (p=0.006 and 0.004), Child-Pugh B (p=0.003 and 0.001) severe stage of disease (p=0.000); comorbidities: Cardiovascular (p=0.016 and 0.009), respiratory (p=0.024 and 0.02), cirrhosis (p=0.033 and 0.01). Conclusion: HRQoL of patients with HCC was poor. Older age, singleness, low education level, poor income, longer duration of disease and treatment, stage of disease and comorbidities reduced the HRQoL.    

Article Details

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A cancer journal for clinicians 68(6): 394-424.
2. Kim HJ, Chu H, Lee S (2018) Factors influencing on health-related quality of life in South Korean with chronic liver disease. Health and Quality of Life Outcomes 16: 142 https://doi.org/10.1186/s12955-018-0964-1.
3. Che YH, You J, Chongsuvivatwong V, Li L, Sriplung H, Yan YZ, Ma SJ, Zhang X, Shen T, Chen HM, Rao SF, Zhang RY (2014) Dynamics and liver disease specific aspects of quality of life among patients with chronic liver disease in Yunnan, China. Asian Pac J Cancer Prev 15(12): 4765-4771.
4. Mai VQ, Sun S, Minh HV, Luo N, Giang KB, Lindholm L, Sahlen KG (2020) An EQ 5D 5L value set for Vietnam. Quality of Life Research 29: 1923-1933. https://doi.org/10. 1007/s11136-020-02469-7.
5. Thái Doãn Kỳ (2015) Nghiên cứu kết quả điều trị ung thư biểu mô tế bào gan kích thước trên 4cm bằng phương pháp hóa tắc mạch với hạt vi cầu tải hóa chất. Luận án Tiến sĩ Y học. Viện nghiên cứu khoa học Y dược lâm sàng 108.
6. Poon RT, Fan ST, Yu WC, Lam BK, Chan FY, Wong J (2001) A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg 136: 693-699.
7. Gutteling JJ, de Man RA, Busschbach JJ, Darlington AS (2007) Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 65(7): 227-234.
8. Huỳnh Nguyễn Phương Quang, Nguyễn Thị Hồng Thuận, Huỳnh Nguyễn Phương Thảo (2021) Chất lượng cuộc sống và một số yếu tố liên quan ở người bệnh ung thư điều trị tại Bệnh viện Ung bướu thành phố Cần Thơ năm 2020. Tạp chí Y học dự phòng, tập 31, số 9, tr. 153-161.
9. Freemantle N, Mollon P, Meyer T, Cheng AL, El-Khoueiry AB, Kelley RK, Baron AD, Benzaghou F, Mangeshkar M, Abou-Alfa GK (2022) Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. European Journal of Cancer 168: 91-98.